The
aggregation of Tau protein, which are involved in Alzheimer’s
disease, are associated with the self-assembly of the hexapeptide
sequence, paired helical filament 6 (PHF6) from repeat 3 of Tau. In
order to treat Alzheimer’s disease and other such tauopathies,
one of the therapeutic strategies is to inhibit aggregation of Tau
and its nucleating segments. Therefore, we have studied the effect
of adenosine triphosphate (ATP) on the aggregation of PHF6. ATP has,
interestingly, demonstrated its ability to inhibit and dissolve protein
aggregates. Using classical molecular dynamics simulations, we observed
that the hydrophobic core of PHF6 segment displays extended β-sheet
conformation, which stabilizes PHF6 aggregates. However, the distribution
of ATP around the vicinity of the peptides enables PHF6 to remain
discrete and attain random coil conformers. The interpeptide interactions
are substituted by PHF6–ATP interactions through hydrogen bonding
and hydrophobic interactions (including π–π stacking).
Furthermore, the adenosine moiety of ATP contributes more than the
triphosphate chain toward PHF6–ATP interaction. Ultimately,
this work establishes the inhibitory activity of ATP against Tau aggregation;
hence, the therapeutic effect of ATP should be explored further in
regard to the effective treatment of Alzheimer’s disease.